Pyridine Pharmaceutical Composition for Lower-Dose Diabetes Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for lifestyle-related diseases such as type 2 diabetes and obesity-related conditions, particularly those involving metformin, require high dosages and have significant side effects, necessitating a more effective and lower dosage alternative.
Innovation Solution
A pharmaceutical composition containing the pyridine derivative HPH-15, which activates AMPK and reduces fat accumulation, is developed to treat lifestyle-related diseases including type 2 diabetes and obesity-related conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If metformin is used to treat type 2 diabetes, then blood glucose regulation is achieved, but high dosage and side effects occur
Solution Approach 1:
The patent changes the chemical structure parameters by introducing a pyridine derivative (HPH-15) with specific molecular characteristics that enhance AMPK activation efficiency. This structural parameter change allows for lower dosage requirements while maintaining blood glucose regulation effectiveness and reducing side effects compared to conventional metformin.
Solution Approach 2:
The patent creates a new pharmaceutical compound (HPH-15) that copies the beneficial mechanism of metformin (AMPK activation) but with improved pharmacological properties. This copying approach allows retention of the effective blood glucose regulation function while eliminating the harmful side effects associated with high metformin dosages.
2Reliability
If metformin is used to treat type 2 diabetes, then blood glucose regulation is achieved, but large dosage is required
Solution Approach 1:
The patent modifies the pharmacological parameters of the active ingredient by using a pyridine derivative structure that has higher binding affinity and activation efficiency for AMPK. This parameter change results in enhanced drug efficacy, allowing for reduced dosage requirements while maintaining effective blood glucose regulation.
Solution Approach 2:
The patent develops a new compound (HPH-15) that replicates the therapeutic mechanism of metformin through AMPK activation but with superior pharmacokinetic properties. This copying strategy enables achieving the same blood glucose regulation at lower dosages by improving the drug's bioavailability and cellular uptake efficiency.
3Reliability
If HPH-15 is used to lower blood glucose, then glucose reduction is achieved, but fat accumulation reduction mechanism was unknown
Solution Approach 1:
The patent demonstrates that HPH-15 possesses multiple functions: it activates AMPK to lower blood glucose levels while simultaneously inhibiting fat accumulation. This multi-functionality is achieved through the compound's ability to regulate both glucose metabolism and lipid metabolism pathways through AMPK activation, resolving the previously unknown connection between HPH-15 and fat accumulation reduction.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
HPH-15 effectively lowers blood glucose levels and reduces fat accumulation, offering a potential treatment for type 2 diabetes, its complications, and obesity-related diseases with reduced side effects and lower dosages compared to metformin.
Implementation Method 1
a biguanide diabetes drug, which is an activator of AMPK (AMP-activated protein kinase), not only regulates blood glucose but also improves insulin resistance, reduces fat production
Data Source
AI summary
A pharmaceutical composition for treating lifestyle-related diseases including type 2 diabetes and obesity-related disease. The pharmaceutical composition includes a compound represented by the following formula (1) or a salt thereof as an active ingredient.